The HER2therapy market is projected to grow from USD 16.8 billion in 2026 toUSD 38.7 billion by 2036, registering a CAGR of 8.7%, according to FutureMarket Insights. The market is gaining momentum as advances in biomarkertesting expand treatment eligibility and pharmaceutical companies developtargeted therapies for HER2-positive, HER2-low, and HER2-ultralow cancers.

The market is expected to add approximately USD 21.9 billionin absolute value between 2026 and 2036. Monoclonal antibodies are projected toremain the leading drug class, while HER2-positive breast cancer represents thedominant indication and injectable therapies account for the largest route ofadministration.

Get Access ofResearch Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-34934

HER2-Targeted Therapies Expand Across Broader PatientPopulations

HER2-targeted treatment is becoming increasingly relevant asbiomarker classification expands beyond traditional HER2-positive disease. Theidentification of HER2-low and HER2-ultralow tumors is creating additionaltreatment opportunities for patients who previously would not have beenconsidered eligible for certain HER2-directed therapies.

Regulatory developments are also influencing the market. InJanuary 2025, the FDA expanded trastuzumab deruxtecan for HER2-low andHER2-ultralow breast cancer using an approved diagnostic assay, increasing theimportance of companion diagnostics and validated biomarker testing intreatment selection.

Future Market Insights is a market research company thatprovides market intelligence on global industries, including market sizing,forecasts, segmentation, competitive analysis, and regional trends.

The expansion of biomarker-defined patient populations isstrengthening the connection between pathology laboratories, companiondiagnostics, and targeted oncology treatment. Consistent HER2 assessment andbreast cancer subtyping are becoming increasingly important components oftreatment decision-making.

Monoclonal Antibodies Lead the Drug Class Segment

Monoclonal antibodies are projected to account for 42.0%of drug class demand in 2026, making them the leading category.

Established therapies such as trastuzumab and pertuzumabcontinue to form important components of HER2-targeted treatment strategies.Their use across different stages of HER2-positive disease supports recurringdemand for antibody-based therapies.

The drug class is also evolving as pharmaceutical companiesinvestigate new combinations, sequencing strategies, and approaches designed toaddress treatment resistance. These developments could broaden the role ofantibody-based therapies across earlier and advanced disease settings.

HER2-Positive Breast Cancer Dominates the IndicationSegment

HER2-positive breast cancer is projected to account for 61.0%of the indication segment in 2026.

The leading position of HER2-positive breast cancer reflectsthe established use of targeted therapies across early-stage and metastaticdisease. Biomarker-guided treatment has become an important component of breastcancer management, creating sustained demand for HER2-directed therapies.

Expansion into HER2-low and HER2-ultralow disease isadditionally broadening the potential patient population. As diagnosticclassification becomes more precise, treatment decisions increasingly depend onvalidated laboratory testing and consistent reporting.

Injectable Therapies Lead the Route of Administration

Injectable therapies are projected to represent 74.0% ofroute-of-administration demand in 2026.

The strong position of injectable therapies is linked to theadministration requirements of established monoclonal antibodies andantibody-drug conjugates. Many of these treatments are administered underclinical supervision, supporting demand across hospitals and specializedoncology centers.

Healthcare providers must manage infusion-relatedrequirements, treatment monitoring, and patient follow-up alongside drugadministration. These operational considerations contribute to the continuedimportance of healthcare facilities in HER2 therapy delivery.

Companion Diagnostics Become More Important to TreatmentSelection

The expansion of HER2-defined treatment categories isincreasing the importance of companion diagnostics. Validated assays can helpidentify patients whose tumors meet the biomarker criteria for specifictherapies.

Hospital pathology laboratories therefore play anincreasingly important role in HER2 testing, specimen evaluation, andreporting. Consistency in testing and interpretation is particularly importantas treatment eligibility expands to lower levels of HER2 expression.

The growing connection between diagnostic testing andtargeted oncology is expected to create opportunities for diagnosticdevelopers, pathology laboratories, and healthcare providers.

Treatment Resistance Remains a Major Clinical Challenge

Treatment resistance remains one of the key challengesfacing the HER2 therapy market. Patients can develop resistance to targetedtherapies through biological mechanisms that reduce treatment effectiveness,creating demand for alternative treatment sequences and combination approaches.

Pharmaceutical companies are investigating next-generationantibody-drug conjugates, targeted combinations, and other therapeuticstrategies to address resistant disease.

Clinical management can also become more complex as patientsreceive multiple lines of therapy. Monitoring requirements, treatmentsequencing, and management of therapy-related adverse events can increase theworkload for oncology teams.

Reimbursement Differences Can Influence Market Access

Regulatory approval does not always translate directly intouniform clinical adoption. Reimbursement authorities can apply differentevidence requirements, cost-effectiveness thresholds, and funding policies whenevaluating HER2 therapies.

These differences can create variations in patient accessacross countries. Healthcare systems may also assess the value of therapiesdifferently depending on disease stage, biomarker category, treatmentalternatives, and available clinical evidence.

As HER2-directed treatments expand into newbiomarker-defined populations, reimbursement decisions are expected to remainan important factor shaping commercial uptake.

Pulmonary Monitoring and Treatment Management AddClinical Complexity

Some HER2-targeted therapies require careful monitoring fortreatment-related complications, including pulmonary adverse events associatedwith certain antibody-drug conjugates.

The need for appropriate patient selection, monitoring, andfollow-up can influence treatment pathways and healthcare resource utilization.Oncology centers therefore require protocols that integrate biomarkerconfirmation, therapy administration, adverse-event monitoring, and ongoingassessment.

These requirements create opportunities for healthcareproviders to strengthen multidisciplinary oncology care and treatmentmonitoring capabilities.

Access Full Report: https://www.futuremarketinsights.com/reports/her2-therapy-market

Competitive Landscape

The HER2 therapy market includes major pharmaceuticalcompanies with established oncology portfolios and emerging biotechnologydevelopers. Key players identified by Future Market Insights include RocheHolding AG, AstraZeneca PLC, Daiichi Sankyo Company, Limited, Pfizer Inc.,Merck & Co., Inc., Amgen Inc., Zymeworks Inc., and Jazz Pharmaceuticals plc.

Competition is centered on treatment efficacy,biomarker-defined eligibility, safety profiles, resistance management,therapeutic sequencing, and differentiation across HER2-positive and HER2-lowpopulations.

Antibody-drug conjugates and next-generation targetedtherapies are important areas of competitive development. Companies are alsostrengthening diagnostic and treatment strategies designed to identify patientsmost likely to benefit from specific HER2-directed therapies.

Future Outlook

The HER2 therapy market is forecast to reach USD 38.7billion by 2036, rising from USD 16.8 billion in 2026. The market isexpected to expand at an 8.7% CAGR, adding approximately USD 21.9billion in absolute value during the forecast period.

Monoclonal antibodies are projected to maintain theirleading position with a 42.0% share of drug class demand in 2026, whileHER2-positive breast cancer is expected to command 61.0% of the indicationsegment. Injectable therapies are projected to account for 74.0% ofroute-of-administration demand.

Broader biomarker-based eligibility, expansion into HER2-lowand HER2-ultralow disease, companion diagnostic adoption, and continueddevelopment of targeted therapies are expected to drive market growth. At thesame time, treatment resistance, pulmonary monitoring requirements,reimbursement differences, and unequal access may influence the pace ofadoption across healthcare systems.

Why FMI: https://www.futuremarketinsights.com/why-fmi

Related Reports:

· https://www.openpr.com/news/4620360/dental-x-ray-systems-market-outlook-next-generation-imaging

· https://www.openpr.com/news/4620364/handheld-dental-x-ray-systems-market-gains-momentum-as-wireless

· https://www.openpr.com/news/4620367/dental-operatory-products-market-set-to-reach-usd-9-77-billion

Contact Us:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware - 19713, USA

T: +1-347-918-3531

For Sales Enquiries: [email protected]

Website: https://www.futuremarketinsights.com

About Future Market Insights (FMI)

Future Market Insights, Inc. (FMI) is an ESOMAR-certified,ISO 9001:2015 market research and consulting organization, trusted by Fortune500 clients and global enterprises. With operations in the U.S., UK, India, andDubai, FMI provides data-backed insights and strategic intelligence across 30+industries and 1200 markets worldwide.